1. Understanding the Termination of Urologic Cancer Clinical Trials: Insights and Challenges
- Author
-
Abdulrahman Alhajahjeh, Majedah Hmeidan, Mus'ab Elatrsh, Faris Al-Abbadi, Diala Kakish, Razan Sukerji, Mohammad Salah, Bashir Al Hussein Al Awamlh, David I. Lee, and Mohammed Shahait
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
PURPOSEClinical trials are valuable evidence for managing urologic malignancies. Early termination of clinical trials is associated with a waste of resources and may substantially affect patient care. We sought to study the termination rate of urologic cancer clinical trials and identify factors associated with trial termination.METHODSA cross-sectional search of ClinicalTrials.gov identified completed and terminated kidney, prostate, and bladder cancer clinical trials started. Trials were assessed for reasons for termination. Multivariable analyses were conducted to determine the significant factors associated with the termination.RESULTSBetween 2000 and 2020, 9,145 oncology clinical trials were conducted, of which 11.30% (n = 1,033) were urologic cancer clinical trials. Of the urologic cancer clinical trials, 25.38% (n = 265) were terminated, with low patient accrual being the most common reason for termination, 52.9% (n = 127). Multivariable analysis showed that only the university funding source odds ratio (OR) of 2.20 (95% CI, 1.45 to 3.32), single-center studies OR of 2.11 (95% CI, 1.59 to 2.81), and sample size of
- Published
- 2024
- Full Text
- View/download PDF